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Considering the cardioprotective and anti-inflammatory properties of clofibrate, the aim of the present experiment was to
investigate the involvement of local and systemic inflammatory cytokines in possible antiarrhythmic effects of clofibrate in ouabain-
induced arrhythmia in rats. Rats were orally treated with clofibrate (300mg/kg), and ouabain (0.56mg/kg) was administered
to animals intraperitoneally. After induction of anesthesia, the atria were isolated and the onset of arrhythmia and asystole
was recorded. The levels of inflammatory cytokines in atria were also measured. Clofibrate significantly postponed the onset
of arrhythmia and asystole when compared to control group (𝑃 ≤ 0.05 and 𝑃 ≤ 0.01, resp.). While ouabain significantly
increased the atrial beating rate in control group (𝑃 ≤ 0.05), same treatment did not show similar effect in clofibrate-treated
group (𝑃 > 0.05). Injection of ouabain significantly increased the atrial and systemic levels of all studied inflammatory cytokines
(𝑃 ≤ 0.05). Pretreatment with clofibrate could attenuate the ouabain-induced elevation of IL-6 and TNF-𝛼 in atria (𝑃 ≤ 0.01 and
𝑃 ≤ 0.05, resp.), as well as ouabain-induced increase in IL-6 in plasma (𝑃 ≤ 0.05). Based on our findings, clofibrate may possess
antiarrhythmic properties through mitigating the local and systemic inflammatory factors including IL-6 and TNF-𝛼.
1. Background
The fibrate class of hypolipidemic drugs is used extensively
in treatment of metabolic syndrome in which hyperlipidemia
and hypertension are most prominent manifestations of this
disorder. Fibrates are ligands of the peroxisome proliferator-
activated receptors (PPARs) [1, 2].These receptors are ligand-
dependent transcription factors and belong to the nuclear
steroid/thyroid/retinoic acid receptor superfamily [3, 4].
PPARs consisted of three isotypes including 𝛼, 𝛽, and 𝛾.
PPAR-𝛼 possesses an important role in lipid metabolism
[5]. PPAR-𝛼 is predominantly expressed in tissues with
high fatty acid oxidation rate including heart, liver, and
kidney [6]. It has been shown that fibrates protect heart
against experimental ischemia/reperfusion injury in ani-
mals through PPARs [7, 8]. Interestingly, previous studies
have shown that cardioprotective effects of fibrates are not
observed in PPAR-𝛼 knockout mice, indicating that PPAR-
𝛼 plays a critical role in cardioprotective effects of fibrates
[7, 8]. Since majority of hyperlipidemic patients are suffering
from comorbid cardiovascular diseases, it is clear that many
of the cardiovascular patients use clofibrate. It has been
demonstrated that PPAR-𝛼 agonists have anti-inflammatory
properties [9–12], and inflammatory cytokines have been
reported to be involved in atrial and ventricular arrhythmias
[13–15].Therefore, the aim of present study was to investigate
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Figure 1: Time of onset of arrhythmia and asystole after ouabain
incubation in vehicle- and clofibrate-treated groups. Data are shown
as mean ± SEM. Six rats were used in each group. ∗𝑃 ≤ 0.05
compared to arrhythmia of vehicle group; ∗∗𝑃 ≤ 0.05 compared to
asystole of vehicle group.
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Figure 2: Atrial beating rates before and after incubation of ouabain
in vehicle- and clofibrate-treated groups. Data are shown as mean ±
SEM. Six rats were used in each group. ∗𝑃 ≤ 0.05 compared to before
time of vehicle group.
the effects of clofibrate on ouabain-induced arrhythmia in
isolated rat atria and involvement of local and systemic
inflammatory cytokines.
2. Material and Methods
2.1. Animals. Male Wistar albino rats (body weight 250–
280 g) were obtained from the Department of Pharmacol-
ogy and Comparative Biology Unit (Tehran University of
Medical Sciences). Animals were housed under the standard
laboratory conditions, temperature 22 ± 2∘C, humidity 70%–
80%, and 12 h light-dark cycle, and have ad libitum access
to food and water. All experiments were conducted in
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Figure 3: Contractile force before and after incubation of ouabain
in vehicle- and clofibrate-treated groups. Data are shown as mean ±
SEM. Six rats were used in each group.
Tehran University of Medical Sciences in accordance with
the recommendations of the ethics committee on animal
experimentation of the medical school.
2.2. Chemicals. All materials were purchased from Merck
(Germany), unless noted otherwise. Clofibrate was a gift
from Zahravi Pharmaceutical Company, Iran. Ouabain and
enzyme-linked immunosorbent assay (ELISA) kit for mea-
surement of IL-6 and TNF-𝛼 were provided from Sigma-
Aldrich (St. Louis, MO, USA). ELISA kit for measurement of
IL-1𝛽 was purchased from Abcam, UK.
2.3. Experimental Plan. In order to study the isolated atria, 12
rats were randomly divided into 2 equal groups. First group
(treatment) received clofibrate (300mg/kg dissolved in olive
oil 1mL/kg, orally) once daily for 14 days, while the second
group (control) received only olive oil (1mL/kg, orally) once
daily for 14 days. For measuring the inflammatory cytokines,
12 rats were divided into three equal groups. First 2 groups
received only olive oil (1mL/kg, orally) once daily for 14 days,
while third group was given clofibrate (300mg/kg, dissolved
in olive oil 1mL/kg, orally) once daily for 14 days. From the
days 12th to 14th, first group received normal saline, 1mL/kg,
intraperitoneally (i.p.) once daily, whereas the second and
third groups were injected by ouabain dissolved in normal
saline at the dose of 0.56mg/kg [16] once daily (i.p.) for three
consecutive days.
2.4. Preparation of Isolated Atria. After induction of anes-
thesia with ketamine (80mg/kg, Alfasan, Netherlands) and
diazepam (2mg/kg, Caspian Tamin, Iran) (i.p.), heart was
rapidly removed and atria were carefully dissected from
the ventricles, attached to a tissue holder, and then were
immersed in a tissue bath containing 25mL of carbogenated
(95% O
2
and 5% CO
2
) modified Krebs solution at 37∘C and
pH 7.4.The composition of the solution was as follows (mM):
NaCl 118.0, KCl 4.7, CaCl
2
2.6, MgCl
2
1.2, NaH
2
PO
4
1.0,
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Figure 4: A general comparison in chronotropic and inotropic features between vehicle- and clofibrate-treated groups. Complete records
of isolated atrial beats of vehicle-treated (a) and clofibrate-treated (b) groups. In vehicle-treated group (a), ouabain-induced arrhythmia
is obvious and asystole happens after arrhythmia. The severity of arrhythmia in clofibrate-treated group is lesser and, in some samples
(b), no asystole was seen until several hours. Atrial beatings before incubation of ouabain in vehicle-treated (c) and clofibrate-treated (d)
groups. As shown, atrial beatings and contractile force are similar in both groups. Ouabain-induced arrhythmia in vehicle-treated (e) and
clofibrate-treated (f) groups.The shape of arrhythmia in vehicle-treated group is bigeminy (twin spikes with strong force), which is the typical
manifestation of ouabain-induced arrhythmia (a). In clofibrate-treated group (b), spikes of arrhythmia are weak and irregular, and it happens
much later than vehicle-treated group. Ouabain-induced asystole in vehicle-treated (g) and clofibrate-treated (h) groups. Time of onset of
asystole in clofibrate-treated group (h) is later than vehicle-treated group.
NaHCO
3
25.0, glucose 11.1, EDTA 0.004, and ascorbic acid
0.11. A preload tension of 1000mg was applied to the atria
and tissues were allowed to equilibrate for 30min [17]. The
rate and force of spontaneous contractions were recorded by
the isometric force transducer of PowerLab system (ADIn-
strument, Australia). Atrial beats and contractile forces were
calculated using the LabChart software.
2.5. Measurement of IL-1𝛽, IL-6, and TNF-𝛼 in Atria and
Plasma. The levels of inflammatory cytokines in atria and
plasma were measured by specific ELISA kits. Briefly, each
atriumwas homogenized in 1mLof phosphate buffered saline
(PBS, pH 7.4) and then centrifuged at 10000 g for 15min at
4∘C. For measurement of plasma levels of cytokines, blood
samples were taken and centrifuged at 4000 g for 15min
at 4∘C. IL-1𝛽, IL-6, and TNF-𝛼 levels were measured by
adding the sample supernatant and kit reagents to plate wells.
Absorbance was read at 450 nm using a plate reader (Synergy
HT, Biotek, USA), and the contents of IL-1𝛽, IL-6, and TNF-𝛼
in atria and plasma were calculated and reported as ng/mL.
2.6. Statistical Analysis. Statistical analyses were carried out
using GraphPad Prism 5 software (San Diego, CA, USA).The
results are presented as mean ± SEM. Unpaired Student’s 𝑡-
test was carried out to compare the time of onset of arrhyth-
mia or asystole as well as atrial beating rate and contractile
force between treatment and control groups. Paired Student’s
𝑡-test was used to detect the effects of ouabain on atrial
beating rate and contractile force within groups. Comparison
of inflammatory cytokines between three groups was done
by one-way analysis of variance (ANOVA) followed by
Tukey’s post hoc test. 𝑃 values less than 0.05 were considered
statistically significant.
3. Results
3.1. Study of Isolated Atria. Clofibrate significantly postponed
time of onset of arrhythmia (23.57 ± 4.69min) rather than
control group (2.04 ± 0.27min, 𝑃 ≤ 0.05). Also, we detected
a significant increase in the onset time of asystole in the
treatment group (66.19 ± 12.33min), while this time for
control group was 22.77 ± 7.17min (𝑃 ≤ 0.01, Figure 1).
Treating with ouabain significantly increased the atrial
beating rate in the control group (194 before and 251 beats per
min after ouabain incubation,𝑃 ≤ 0.05), while such effectwas
not observed in treatment group (198 before and 199 beats per
min after ouabain incubation, 𝑃 > 0.05, Figure 2).
Treatment with ouabain had no effect on contractile force
in both groups (0.627 g before and 0.663 g after ouabain
incubation for the control group, 𝑃 > 0.05, and 0.569 g
before and 0.573 g after ouabain incubation for the treatment
group, 𝑃 > 0.05, Figure 3). There was also no significant
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Figure 5: Atrial levels of IL-6 (a), TNF-𝛼 (b), and IL-1𝛽 (c) in saline- and ouabain-injected vehicle- and clofibrate-treated groups. Data are
shown as mean ± SEM. Four rats were used in each group. ∗𝑃 ≤ 0.01 and ∗∗𝑃 ≤ 0.001 compared to saline-injected vehicle-treated group;
#
𝑃 ≤ 0.05 and ##𝑃 ≤ 0.01 compared to ouabain-injected vehicle-treated group.
difference in atrial beating rate and contractile force between
the two groups before incubation with ouabain (𝑃 > 0.05
for atrial beating rate, Figure 2, and 𝑃 > 0.05 for contractile
force, Figure 3). Figure 4 represents a general comparison in
chronotropic and inotropic features between both groups,
but the intensity of arrhythmia in the control group (a) was
greater than the treatment group (b). Time of onset of asystole
was also observed earlier in control group (a). The shapes
of the spikes were normal in both groups before incubation
of ouabain (c, d). Figure 4(e) obviously shows the ouabain-
induced arrhythmia in control group, while the severity of
this arrhythmia is smaller in treatment group (f).
3.2. Levels of IL-1𝛽, IL-6, and TNF-𝛼 in Atria and Plasma.
As shown in Figure 5, injection of ouabain significantly
increased the atrial levels of all studied inflammatory
cytokines (𝑃 ≤ 0.01 for IL-1𝛽 and IL-6 and 𝑃 ≤ 0.001 for
TNF-𝛼). Pretreatmentwith clofibrate attenuated the ouabain-
induced elevation of IL-6 and TNF-𝛼 in atria (𝑃 ≤ 0.01 and
𝑃 ≤ 0.05, resp., Figures 5(a) and 5(b)), while it failed to
decrease the ouabain-induced elevation in IL-1𝛽 (𝑃 > 0.05,
Figure 5(c)).
Similarly, ouabain boosted the plasma levels of all inflam-
matory cytokines significantly (𝑃 ≤ 0.001, 𝑃 ≤ 0.05,
and 𝑃 ≤ 0.01 for IL-1𝛽, IL-6, and TNF-𝛼, resp., Figure 6).
Nevertheless, pretreatment with clofibrate could only reverse
the ouabain-induced elevation of IL-6 in plasma (𝑃 ≤ 0.05,
Figure 6(a)), whereas it did not reduce the ouabain-induced
increase in TNF-𝛼 and IL-1𝛽 levels in plasma (𝑃 > 0.05,
Figures 6(b) and 6(c)).
4. Discussion
Cardiac arrhythmias are life-threatening medical conditions.
As most antiarrhythmic drugs have serious adverse effects,
finding safer antiarrhythmic agents with less side effects
has been suggested in the literature. In the present study,
we investigated the effects of clofibrate on ouabain-induced
arrhythmia in isolated rat atria. For this purpose, induction
of arrhythmia and measurement of inflammatory cytokines
were performed in rats given ouabain or vehicle. Our results
showed that clofibrate, as a PPAR-𝛼 agonist, succeeded to
induce antiarrhythmic effects by delaying the onset and
reducing the intensity of ouabain-induced arrhythmias and
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Figure 6: Plasma levels of IL-6 (a), TNF-𝛼 (b), and IL-1𝛽 (c) in saline- and ouabain-injected vehicle- and clofibrate-treated groups. Data
are shown as mean ± SEM. Four rats were used in each group. ∗𝑃 ≤ 0.05, ∗∗𝑃 ≤ 0.01, and ∗∗∗𝑃 ≤ 0.001 compared to saline-injected
vehicle-treated group; #𝑃 ≤ 0.05 compared to ouabain-injected vehicle-treated group.
reduction of ouabain-induced elevation of inflammatory
cytokines especially IL-6 in isolated rat atria. In addi-
tion, clofibrate alleviated the positive chronotropic effect of
ouabain.
It has been reported that ouabain induces the production
of proinflammatory cytokines. For example, Matsumori et
al. showed that incubation of ouabain increased the levels of
IL-1𝛼, IL-1𝛽, and IL-6 in cultured human peripheral blood
mononuclear cells [18]. They also reported that ouabain
is able to increase the production of TNF-𝛼 [19]. In line
with previous studies, we showed that ouabain increased
proinflammatory cytokines (IL-1𝛽, IL-6, and TNF-𝛼 in both
of atria and plasma, Figures 5 and 6), in the atria of treated
rats. Furthermore, we demonstrated that clofibrate decreased
the inflammatory cytokines in atria (IL-6 and TNF-𝛼, Figures
5(a) and 5(b)) and plasma (IL-6, Figure 6(a)). In this regard,
Jiang et al. reported that PPAR-𝛾 agonists could suppress
phorbol ester-induced elevation of IL-1𝛽, IL-6, and TNF-𝛼
[20]. Additionally, it has been shown that PPAR-𝛾 agonists
improve insulin resistance through inhibiting the effect of
TNF-𝛼 in adipocytes [21]. Although these reports mentioned
the protective effects of PPAR-𝛾 receptor agonists against
inflammatory cytokines, we found such effects in case of
PPAR-𝛼 receptor agonist.
Inflammatory cytokines play a key role in mediating
the inflammatory responses under pathologic conditions.
TNF-𝛼 and IL-1 stimulate the release of other inflammatory
cytokines such as IL-6 [22]. Evidence indicates that atrial
fibrillation after coronary artery bypass grafting is associated
with increase in IL-6 in patients [23, 24]. Similar studies
have reported that atrial fibrillation results in sequestration
of inflammatory cytokines in the heart [13, 14]. With IL-
6, there are numerous published studies that suggest that
TNF-𝛼 (and to some extent IL-1𝛽) possess arrhythmogenic
properties. In this context, TNF-𝛼 and IL-1𝛽 have been
reported to boost susceptibility to arrhythmia in rat ven-
tricular myocytes through increase of calcium leakage from
the sarcoplasmic reticulum [15]. Moreover, it is frequently
reported that overexpression of TNF-𝛼 in transgenic ani-
mals causes various atrial and ventricular arrhythmias [25–
28]. Recent evidence suggests that inflammatory factors,
mainly TNF-𝛼, contribute to pathophysiology of ventricular
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arrhythmias [29]. These findings justify the results of the
present study and strengthened our hypothesis that local
and systemic inhibition of inflammatory cytokines modulate
antiarrhythmic properties of PPAR-𝛼 agonist, clofibrate. It
seems that the role of IL-6 in mediating the antiarrhythmic
properties of clofibrate is more prominent than TNF-𝛼,
because clofibrate reduced IL-6, locally and systemically,
while it only decreased the local elevation of TNF-𝛼. On
the other hand, the local antiarrhythmic effects of clofibrate
appear superior to systemic antiarrhythmic properties.
Several lines of research have indicated that there is a
high rate of atrial fibrillation and other kinds of cardiac
arrhythmias in metabolic syndrome and lipid metabolism
disorders [30, 31]. Evidence shows that pretreatment with
PPAR-𝛼 agonist, clofibrate, can reduce the experimental
myocardial infarct size up to 43% in rats [32], and it is well
established that cardiac infarction and ischemia can cause
the most types of arrhythmias. Tabernero et al. and Yue
et al. have also reported that PPAR-𝛼 agonists protect the
heart against the ischemia-reperfusion injury [7, 8]. Since
clofibrate modulates lipid metabolism, this effect might also
partly explain its antiarrhythmic properties, which could
be investigated in future studies. Although we did not use
ischemia-reperfusion model for induction of arrhythmia in
the present study, clofibrate could significantly postpone the
time of onset of arrhythmia and asystole in ouabain-induced
arrhythmias.
5. Conclusions
It is concluded that clofibrate might possess antiarrhythmic
properties in reducing the cardiac arrhythmias. It seems that
clofibrate shows this beneficial effect through themodulation
of some local and systemic inflammatory cytokines including
IL-6 and TNF-𝛼.
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